bisoprolol has been researched along with Diabetes Mellitus, Type 2 in 17 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Given that it has been reported that type 2 diabetes mellitus may affect the pharmacokinetics of a large number of drugs and that there are still no published population pharmacokinetic (PopPK) analyses in routinely treated patients with hypertension and type 2 diabetes mellitus as comorbid condition, the aim of this study was to determine PK variability of bisoprolol in 70 Serbian patients using the PopPK approach." | 7.96 | Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension. ( Janković, SM; Jovanović, A; Milovanović, JR; Momčilović, S; Nikolić, VN; Pešić, M; Radojković, D, 2020) |
| "The beneficial effects of the beta-blocker bisoprolol on mortality and rate of hospitalisation as well as its safety in patients with chronic heart failure has been proven." | 7.71 | Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. ( Erdmann, E; Lechat, P; Verkenne, P; Wiemann, H, 2001) |
| "In a double-blind crossover study, the influence of bisoprolol and placebo was tested in 20 noninsulin-dependent diabetics with concomitant essential hypertension." | 5.06 | Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. ( Disselhoff, G; Janka, HU; Mehnert, H; Ziegler, AG, 1986) |
| "Given that it has been reported that type 2 diabetes mellitus may affect the pharmacokinetics of a large number of drugs and that there are still no published population pharmacokinetic (PopPK) analyses in routinely treated patients with hypertension and type 2 diabetes mellitus as comorbid condition, the aim of this study was to determine PK variability of bisoprolol in 70 Serbian patients using the PopPK approach." | 3.96 | Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension. ( Janković, SM; Jovanović, A; Milovanović, JR; Momčilović, S; Nikolić, VN; Pešić, M; Radojković, D, 2020) |
| "The influence of beta-blocker therapy (bisoprolol or carvedilol) (bB) on the prognosis of heart failure (HF) patients with diabetes mellitus (DM) is uncertain." | 3.81 | Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus. ( Andrey, JL; Aranda, RM; Garcia-Egido, A; Gomez, F; López-Sáez, JB; Pedrosa, MJ; Puerto, JL; Rosety, M, 2015) |
| "The beneficial effects of the beta-blocker bisoprolol on mortality and rate of hospitalisation as well as its safety in patients with chronic heart failure has been proven." | 3.71 | Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. ( Erdmann, E; Lechat, P; Verkenne, P; Wiemann, H, 2001) |
| "Type 2 diabetes is becoming very common and is closely linked to physical inactivity and obesity." | 2.41 | Beta-blockers and diabetes: the bad guys come good. ( Cruickshank, JM, 2002) |
| "She had a background of type 2 diabetes, asthma and hypertension." | 1.51 | Case study of thyrotoxic cardiomyopathy. ( Alam, ST; Zaman, J, 2019) |
| "Laughter-induced syncope is considered as one of the many Valsalva-type/vagally mediated syncopal attacks leading to rapid fall in blood pressure without compensatory tachycardia." | 1.35 | [Spasmodic laughter syncope. An unusual complication of pseudobulbar palsy]. ( Awada, A; Halaby, G; Tamraz, J, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Tchernev, G | 1 |
| Alam, ST | 1 |
| Zaman, J | 1 |
| Momčilović, S | 1 |
| Jovanović, A | 1 |
| Radojković, D | 1 |
| Nikolić, VN | 1 |
| Janković, SM | 1 |
| Pešić, M | 1 |
| Milovanović, JR | 1 |
| Bradley, A | 1 |
| Sheridan, P | 1 |
| Garcia-Egido, A | 1 |
| Andrey, JL | 1 |
| Puerto, JL | 1 |
| Aranda, RM | 1 |
| Pedrosa, MJ | 1 |
| López-Sáez, JB | 1 |
| Rosety, M | 1 |
| Gomez, F | 1 |
| Chen, RJ | 1 |
| Chu, H | 1 |
| Tsai, LW | 1 |
| Awada, A | 1 |
| Halaby, G | 1 |
| Tamraz, J | 1 |
| Wai, B | 1 |
| Kearney, LG | 1 |
| Hare, DL | 1 |
| Ord, M | 1 |
| Burrell, LM | 1 |
| Srivastava, PM | 1 |
| Cruickshank, JM | 1 |
| Ivanova, LA | 1 |
| Kanorskii, SG | 1 |
| Rostovtseva, ON | 1 |
| Halil Sufian, B | 1 |
| Galenko-Yaroshevskii, PA | 1 |
| Wang, B | 1 |
| Song, WH | 1 |
| Liu, GZ | 1 |
| Czupryniak, L | 1 |
| Pawłowski, M | 1 |
| Saryusz-Wolska, M | 1 |
| Loba, J | 1 |
| Yudkin, J | 1 |
| Erdmann, E | 1 |
| Lechat, P | 1 |
| Verkenne, P | 1 |
| Wiemann, H | 1 |
| Vulpis, V | 1 |
| Antonacci, A | 1 |
| Prandi, P | 1 |
| Bokor, D | 1 |
| Pirrelli, A | 1 |
| Janka, HU | 1 |
| Ziegler, AG | 1 |
| Disselhoff, G | 1 |
| Mehnert, H | 1 |
1 review available for bisoprolol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Beta-blockers and diabetes: the bad guys come good.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Bisoprolol; Coronary Disease; Diabet | 2002 |
5 trials available for bisoprolol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Treatment of acute coronary syndromes in patients with type 2 diabetes mellitus with beta-adrenoblockers and angiotensin-converting enzyme inhibitors: cardiohemodynamic effects and impact for prognosis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors | 2004 |
[The effect long-term administration of a selective beta1 blocker bisoprolol on glucose metabolism in patients with essential hypertensive and type 2 diabetes mellitus].
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Bisoprolol; Blood Glu | 2005 |
Circadian blood pressure variation and antihypertensive medication adjustment in normoalbuminuric type 2 diabetes patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Circadian Rhythm; Diab | 2007 |
[The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Bisoprolol; Blood Glucose; Diabetes Mellitus, Ty | 1991 |
Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics.
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Blood Glucose; Blood Pressure; Body Weight; Carbohydr | 1986 |
11 other studies available for bisoprolol and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
THE NITROSAMINE CONTAMINATION IN BETA BLOCKERS (BISOPROLOL/METOPROLOL), ACE INHIBITORS (LISINOPRIL/PERINDOPRIL), THIAZIDES DIURETICS (HCT), CALCIUM CHANNEL BLOCKERS (AMLODIPINE/FELODIPINE), SARTANS (CANDESARTAN) AND ТHE SUBSEQUENT SKIN CANCER DEVELOPMENT
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2023 |
Case study of thyrotoxic cardiomyopathy.
Topics: Antihypertensive Agents; Bisoprolol; Bundle-Branch Block; Carbimazole; Cardiomyopathies; Diabetes Me | 2019 |
Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Bisoprolol; Cytochrome P-450 CYP3A; Diabetes Mellitus, Type 2; Femal | 2020 |
Atrial fibrillation.
Topics: Aged; Antihypertensive Agents; Anxiety; Atrial Fibrillation; Bisoprolol; Comorbidity; Diabetes Melli | 2013 |
Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Bisoprolol; Carbazoles; Carvedilol; Case-Control Stud | 2015 |
Impact of Beta-Blocker Initiation Timing on Mortality Risk in Patients With Diabetes Mellitus Undergoing Noncardiac Surgery: A Nationwide Population-Based Cohort Study.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Cohort Studies; Dat | 2017 |
[Spasmodic laughter syncope. An unusual complication of pseudobulbar palsy].
Topics: Adrenergic beta-Antagonists; Aged; Bisoprolol; Brain; Diabetes Mellitus, Type 2; Humans; Laughter; M | 2009 |
Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Biomarkers; Bisoprolol; Carbazole | 2012 |
Beta-blockers in heart failure.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Cardiac Output, Low; Diabetes Mellitus, Type 2; Education, | 1999 |
[Hypertensive diabetic patients. Plus points for selective beta 1-blockade].
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Bisopr | 2001 |
Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Age Distribution; Aged; Aged, 80 and over; Bisoprolol; Cause of Death; | 2001 |